Targeting Proteinuria as a Valid Surrogate for Individualized Kidney Protective Therapy

American Journal of Kidney Diseases

Volumn 51, Issue 5, 2008, Pages 713-716

  de Zeeuw, Dick ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE ASSOCIATION; EDITORIAL; HUMAN; PROTEINURIA; RENAL PROTECTION; RISK FACTOR; TREATMENT PLANNING;

BIOLOGICAL MARKERS; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; PREDICTIVE VALUE OF TESTS; PROTEINS; PROTEINURIA; RISK FACTORS;

EID: 43049117560     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.03.013     Document Type: Editorial

References (31)

1. Lewis E.J., Hunsicker L.G., Bain R.P., and Rohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329 (1993) 1456-1462
2. No authors listed. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 349 (1997) 1857-1863
3. Brenner B.M., Cooper M.E., de Zeeuw D., et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
4. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
5. Agodoa L.Y., Appel L., Bakris G.L., Beck G., et al. African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 285 (2001) 2719-2728
6. De Jong P.E., Navis G., and de Zeeuw D. Renoprotective therapy: titration against urinary protein excretion. Lancet 354 (1999) 352-353
7. Rossing P., Hommel E., Smidt U.M., and Parving H.H. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 37 (1994) 511-516
8. Apperloo A.J., de Zeeuw D., and de Jong P.E. Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int Suppl 45 (1994) S174-S178
9. Taguma Y., Kitamoto Y., Futaki G., et al. Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 313 (1985) 1617-1620
10. Gansevoort R.T., de Zeeuw D., and de Jong P.E. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?. Kidney Int 45 (1994) 861-867
11. van Paassen P., de Zeeuw D., Navis G., and de Jong P.E. Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function. Nephrol Dial Transplant 15 (2000) 637-643
12. Schjoedt K.J., Rossing K., and Juhl T.R. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 68 (2005) 2829-2836
13. de Zeeuw D., Remuzzi G., and Parving H.H. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 65 (2004) 2309-2320
14. Lea J., Greene T., and Hebert L. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 165 (2005) 947-953
15. Atkins R.C., Briganti E.M., and Lewis J.B. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 45 (2005) 281-287
16. Eijkelkamp W.B., Zhang Z., and Remuzzi G. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 18 (2007) 1540-1546
17. Szeto C.-C., Chow K.-M., Kwan Ching-Ha B., et al. Oral Calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial. Am J Kidney Dis 51 (2008) 724-731
18. Schmieder R.E., Klingbeil A.U., Fleischmann E.H., Veelken R., and Delles C. Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol 16 (2005) 3038-3045
19. Rossing K., Schjoedt K.J., Jensen B.R., Boomsma F., and Parving H.H. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 68 (2005) 1190-1198
20. Buter H., Hemmelder M.H., Navis G., de Jong P.E., and de Zeeuw D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 13 (1998) 1682-1685
21. Heeg J.E., de Jong P.E., van der Hem G.K., and de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 36 (1989) 272-279
22. Vogt L., Waanders F., Boomsma F., de Zeeuw D., and Navis G. Effects of Dietary Sodium and Hydrochlorothiazide on the Antiproteinuric Efficacy of Losartan. J Am Soc Nephrol (2008) doi: 10.1681/ASN.2007060693
23. Jacobsen P.K. Preventing end-stage renal disease in diabetic patients - dual blockade of the renin-angiotensin system (Part II). J Renin Angiotensin Aldosterone Syst 6 (2005) 55-68
24. Nakao N., Yoshimura A., Morita H., Takada M., Kayano T., and Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 361 (2003) 117-124
25. Agarwal R., Acharya M., Tian J., Hippensteel R.L., Melnick J.Z., Qiu P., Williams L., and Batlle D. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 68 (2005) 2823-2828
26. Abbott: A Study of Paricalcitol Capsules on Reducing Albuminuria in Type 2 Diabetic Nephropathy Being Treated With Renin-Angiotensin System Inhibitors. http://clinicaltrials.gov/ct2/show/NCT00421733 Accessed March 28, 2008
27. Gansevoort R.T., de Zeeuw D., and de Jong P.E. Additive antiproteinuric effect of ACE inhibition and a low-protein diet in human renal disease. Nephrol Dial Transplant 10 (1995) 497-504
28. Perico N., Remuzzi A., Sangalli F., Azzollini N., Mister M., Ruggenenti P., and Remuzzi G. The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. J Am Soc Nephrol 9 (1998) 2308-2317
29. Gambaro G., Kinalska I., and Oksa A. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol 13 (2002) 1615-1625
30. Lambers Heerspink H.J., Fowler M.J., Volgi J., et al., Collaborative Study Group. Rationale for and study design of the sulodexide trials in Type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathy. Diabet Med 24 (2007) 1290-1295
31. Bos H., Andersen S., Rossing P., De Zeeuw D., Parving H.H., De Jong P.E., and Navis G. Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. Kidney Int Suppl 75 (2000) S32-S37